[ad_1]
Illustrative image
Image credit: IANS
Greater Noida: Shiv Nadar University in Greater Noida announced Monday that its researchers have created a molecule that has the potential to become a medicine that can cure Acute Respiratory Distress Syndrome (ARDS) in patients with COVID-19.
The team found a set of new chemical entities (NCEs) with the ability to cure acute respiratory distress syndrome (ARDS) or COVID-19-induced acute lung injury (ALI) (SARS-CoV-2) or another respiratory syndrome acute severe (SARS) and Middle East Respiratory Syndrome (MERS), which are also caused by coronavirus.
The dual strategy developed by the research team involved applying NCEs to inhibit attachment, entry, and infection of the new SARS-CoV-2 through a known target in the virus and co-administration of a known drug ( modulating a set of hormone receptors in humans) and these NCEs to attenuate ARDS caused by the new coronavirus.
“We hope that our therapeutic approach will untangle solutions against diseases associated with acute respiratory distress syndrome. Our goal is to complete the preclinical studies by the end of this year, after which the new compound will potentially be ready for the next stage of development. along with human trials, “study investigator Dr. Subhabrata Sen, a professor in the Department of Chemistry at Shiv Nadar University, said in a statement.
According to the University, the discovery stemmed from months of research, conceptualizing small molecule modulators of a set of hormone receptors in humans and how they are connected to potential receptors in the lungs that act as the input for SARS-CoV-2, SARS, and MERS. in the human host.
In addition, the researchers analyzed the pathophysiological condition of the lungs during respiratory failure. This included extensive investigations of lung samples from patients retrospectively found to have COVID-19.
With these data, they designed the project that helps mitigate acute respiratory distress.
The research team has filed a provisional patent in India to protect the new chemical entities. The new discovery molecule is moving to the next stage of verification where it will be tested for efficacy in animals.
They believe that their therapy will not only prevent COVID-19 from affecting a person’s lungs, but will also address lung injuries already inflicted by the virus, in cases where ventilators do not provide much relief to patients with COVID-19 who suffer from ARDS.
The Shiv Nadar University study was conducted in collaboration with Professor Ralf Jockers, an expert molecular biologist from the Institut Cochin (INSERM, CNRS, the University of Paris in France).
